The Latest
COUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting® 2024
Skip to primary navigation
Skip to main content
Skip to footer
COUR Pharmaceuticals
Our Company
Leadership
Board of Directors
Advisors
Partners
Contact
Our Technology
Pipeline
Our Clinical Trials
CNP-106 Myasthenia Gravis
Publications & Media
Press Releases
Publications
Careers
John J. Puisis
Founder & Former President & CEO